采用小于标准放疗边界不改变高级别胶质瘤患者的生存结局
该研究分析了267例病理确诊高级别胶质瘤患者的治疗计划和结局,比较肿瘤区到计划区边界≤1 cm与标准2–3 cm边界的生存差异。中位无进展生存期和总生存期分别为10.6和19.1个月,1.0 cm边界亚组与0.4 cm边界亚组生存相似,与标准边界比较无显著差异。作者认为缩小边界安全,但尚缺乏I类证据,需进一步研究。
要点
- 267例高级别胶质瘤患者中,中位无进展生存期10.6个月、总生存期19.1个月。
- 1.0 cm边界亚组(n=212)中位无进展生存期10.7个月、总生存期19.1个月。
- 0.4 cm边界亚组(n=55)中位无进展生存期10.2个月、总生存期19.3个月。
核心结论
- 采用小于标准放疗边界与较大边界相比,生存结局无 apparent 差异。
- 目前尚无I类证据表明较小边界治疗后结局与较大边界完全相同,但该大样本长期随访系列提示缩小边界是安全的,需进一步研究。
研究设计与样本
- 对267例病理确诊高级别胶质瘤患者的治疗计划和结局进行分析。
- 生存期从首次放疗时间起计算,采用卡方检验或Fisher精确检验分析边界大小与患者特征的关系。
- 采用Kaplan-Meier法估计生存,log-rank检验进行比较,所有分析均在单变量水平进行。
主要发现
- 中位无进展生存期和总生存期分别为10.6和19.1个月。
- 胶质母细胞瘤中位无进展生存期和总生存期分别为8.6和16.1个月;间变性胶质瘤分别为26.7和52.5个月。
- 中位随访时间为18.3个月。
- 1.0 cm边界亚组(n=212)中位无进展生存期和总生存期分别为10.7和19.1个月;0.4 cm边界亚组(n=55)分别为10.2和19.3个月。
- 与标准2–3 cm边界治疗比较,结局无显著差异。
关键数值与推荐
- 肿瘤区到计划区边界≤1 cm与标准2–3 cm边界比较,生存无显著差异。
- 1.0 cm边界亚组与0.4 cm边界亚组生存结局相当。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出目前尚无I类证据表明较小边界治疗后结局与较大边界完全相同。
- 原文结论提出需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The number of studies that evaluate treatment margins for high grade gliomas (HGG) are limited. We hypothesize that patients with HGG who are treated with a gross tumor volume (GTV) to planning tumor volume (PTV) expansion of ≤1 cm will have progression-free survival (PFS) and overall survival (OS) rates similar to those treated in accordance with standard protocols by the Radiation Therapy Oncology Group or European Organisation for Research and Treatment of Cancer. Furthermore, the PFS and OS of subgroups within the study population will have equivalent survival outcomes with GTV1-to-PTV1 margins of 1.0 cm and 0.4 cm. METHODS AND MATERIALS: Treatment plans and outcomes for patients with pathologically confirmed HGG were analyzed (n = 267). Survival (PFS and OS) was calculated from the time of the first radiation treatment and a χ2 test or Fisher exact test was used to calculate the associations between margin size and patient characteristics. Survival was estimated using Kaplan-Meier and compared using the log-rank test. All analyses were performed on the univariate level. RESULTS: The median PFS and OS times were 10.6 and 19.1 months, respectively. By disease, the median PFS and OS times were 8.6 and 16.1 months for glioblastoma and 26.7 and 52.5 months for anaplastic glioma. The median follow-up time was 18.3 months. The treatment margin had no effect on outcome and the 1.0 cm GTV1-PTV1 margin subgroup (n = 212) showed median PFS and OS times of 10.7 and 19.1 months, respectively, and the 0.4 cm margin subgroup (n = 55) 10.2 and 19.3 months, respectively. In comparison with the standard treatment with 2 cm to 3 cm margins, there was not a significant difference in outcomes. CONCLUSIONS: There is no apparent difference in survival when utilizing smaller versus larger margins as defined by the guidelines of the Radiation Therapy Oncology Group and European Organisation for Research and Treatment of Cancer. Although there remains no class I evidence that outcomes after treatment with smaller margins are identical to those after treatment with larger margins, this large series with long-term follow up suggests that a reduction of the margins is safe and further investigation is warranted.
引用
- Guram K, Smith M, Ginader T, et al. Using Smaller-Than-Standard Radiation Treatment Margins Does Not Change Survival Outcomes in Patients with High-Grade Gliomas. Pract Radiat Oncol. 2018. PMID: 30195927. doi:10.1016/j.prro.2018.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。